B. Riley Lowers Earnings Estimates for Wave Life Sciences

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at B. Riley reduced their FY2026 earnings per share estimates for shares of Wave Life Sciences in a report released on Thursday, April 10th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of ($1.15) for the year, down from their prior forecast of ($0.96). The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences' FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

A number of other research firms have also recently commented on WVE. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a "buy" rating and a $26.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, Wedbush began coverage on Wave Life Sciences in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Wave Life Sciences currently has an average rating of "Moderate Buy" and an average price target of $22.18.

Wave Life Sciences Trading Up 1.4 %

Wave Life Sciences stock traded up $0.08 during trading on Monday, reaching $5.92. The company had a trading volume of 947,955 shares, compared to its average volume of 1,188,466. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74. The firm has a market capitalization of $908.64 million, a price-to-earnings ratio of -5.33 and a beta of -0.93. The firm's 50-day simple moving average is $9.01 and its 200 day simple moving average is $11.57.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million.

Insider Activity at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. This trade represents a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now owns 338,351 shares in the company, valued at approximately $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Wave Life Sciences

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Wave Life Sciences in the fourth quarter worth approximately $40,000. Quarry LP purchased a new position in shares of Wave Life Sciences during the fourth quarter valued at $62,000. KBC Group NV bought a new stake in shares of Wave Life Sciences in the fourth quarter valued at about $67,000. Summit Investment Advisors Inc. grew its holdings in Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after acquiring an additional 2,308 shares in the last quarter. Finally, Orion Portfolio Solutions LLC purchased a new position in Wave Life Sciences during the 3rd quarter valued at about $123,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.